Daha Önce 1 bDMARD Kullananan RA Hastalarında Tofasitinib Gerçek Dünya Deneyiminin Adalimumab, Etanercept ve Abatacept ile Karşılaştırılması: ABD İdari Talep Veritabanı
J Manag Care Spec Pharm. 2016 Dec;22(12):1457-1471.
Data were examined to compare patient characteristics, treatment patterns and costs in patients with RA receiving tofacitinib (TOF) or common bDMARDs (adalimumab [ADA], etanercept (ETN) or abatacept [ABA]) who had previously received a single bDMARD.This study analyses real-world data from two US claims databases between November 2012 and October 2014. Data were collected from a total of 1252 patients in the Truven Marketscan Commercial and Medicare Supplemental databases. Pre-index (12-months b...